Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

被引：0
|
作者：
Buecklein, Veit L. [1 ]
Ayuk, Francis A. [2 ]
Holderried, Tobias A. W. [3 ]
Mai, Christine [4 ]
Kievit, Bradley [5 ]
Blisset, Rob [5 ]
Doble, Brett [6 ]
Reid, Geoff [6 ]
Reimeir, Laura [7 ]
Bruns, Caroline [7 ]
Vadgama, Sachin [6 ]
机构：
[1] LMU Univ Hosp, Dept Med 3, Munich, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany
[3] Univ klinikum Bonn UKB, Bonn, Germany
[4] AplusA, Lyon, France
[5] Maple Hlth Grp LLC, New York, NY USA
[6] Gilead Co, Kite, Santa Monica, CA USA
[7] Gilead Sci GmbH, Munich, Germany
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-205589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5037 / 5038
页数：2
相关论文
共 50 条
  • [41] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
  • [43] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Ayyappan, Sabarish
    Kim, Won Seog
    Kim, Tae Min
    Walewski, Jan
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle
    Oh, Sung Yong
    Lim, Francesca Lorraine Wei Inng
    Carpio, Cecilia
    Tan, Tran-Der
    Gutierrez, Antonio
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Li, Jingjin
    Ufkin, Melanie
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Prince, H. Miles
    BLOOD, 2023, 142
  • [44] CLINICAL FEATURES AND SURVIVAL OF PATIENTS WITH LATE RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Castillo-Giron, C.
    Rivas-Delgado, A.
    Dlouhy, I
    Rovira, J.
    Mozas, P.
    Rivero, A.
    Frigola, G.
    Balague, O.
    Baumann, T.
    Correa, J. G.
    Magnano, L.
    Jimenez-Vicente, C.
    Gomez, M.
    Delgado, J.
    Villamor, N.
    Campo, E.
    Gine, E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2020, 105 : 291 - 292
  • [45] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
    Saverno, Kim
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Epperla, Narendranath
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
  • [46] ROLE OF CAR-T CELLS THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Sen, P.
    Saadeh, B.
    Loh, E.
    VALUE IN HEALTH, 2019, 22 : S440 - S441
  • [47] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Epperla, Narendranath
    Lucero, Melanie
    Bailey, Tom
    Mirams, Laura
    Cheung, Jolenta
    Amet, Mona
    Milligan, Gary
    Chen, Lei
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [48] Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma
    Rozental, Alon
    Chavez, Julio C.
    Sehovic, Marina
    Locke, Frederick L.
    Lazaryan, Aleksandr
    Nishihori, Taiga
    Khimani, Farhad
    Jain, Michael D.
    Shah, Bijal D.
    Extermann, Martine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life Experience
    Buecklein, V.
    Schmidt, C.
    Blumenberg, V.
    Reischer, A.
    von, Baumgarten L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Reilich, S.
    Bauer, M.
    Ostermann, H.
    Tischer, J.
    Stemmler, H-J.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81
  • [50] Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis
    Li, Yin
    Li, Chunfan
    Lv, Kebing
    Wang, Shixuan
    Li, Fei
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e5 - e16
12345